<p>在过去三个月中，21 位分析师分享了他们对 Kymera Therapeutics（纳斯达克：KYMR）的评估，展现出从看涨到看跌的多样化前景。</p>
<p>下表提供了他们最近评级的快速概览，突显了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师对 12 个月价格目标的评估提供了额外的见解，显示出平均目标为 120.05 美元，最高预估为 138.00 美元，最低预估为 80.00 美元。观察到 44.97% 的增长，目前的平均值已从之前的 82.81 美元上升。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png"/></p>
<h2>分析师评级探讨：深入概述</h2>
<p>对金融专家如何看待 Kymera Therapeutics 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及评级和价格目标调整的详细总结。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上调</td>
<td>超配</td>
<td>$133.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>上调</td>
<td>买入</td>
<td>$117.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超配</td>
<td>$103.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>上调</td>
<td>超配</td>
<td>$110.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Mizuho</td>
<td>上调</td>
<td>超配</td>
<td>$120.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>$125.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>上调</td>
<td>买入</td>
<td>$122.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>上调</td>
<td>买入</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>$116.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$116.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>上调</td>
<td>超配</td>
<td>$120.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>$127.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上调</td>
<td>超配</td>
<td>$119.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$125.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>上调</td>
<td>买入</td>
<td>$134.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>上调</td>
<td>超配</td>
<td>$118.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>上调</td>
<td>买入</td>
<td>$112.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>上调</td>
<td>买入</td>
<td>$138.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’，都反映了他们对 Kymera Therapeutics 最近发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师对股票进行定性评估，范围从 ‘超配’ 到 ‘低配’。这些评级传达了分析师对 Kymera Therapeutics 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供 Kymera Therapeutics 未来价值的估计。检查当前和之前的目标提供了分析师预期变化的见解。</li>
</ul>
<p>将这些分析师评估与关键财务指标结合起来，可以提供 Kymera Therapeutics 市场地位的全面概述。保持信息灵通，并在我们的评级表的帮助下做出明智的决策。</p>
<p>随时了解 Kymera Therapeutics 的分析师评级。</p>
<h2>关于 Kymera Therapeutics</h2>
<p>Kymera Therapeutics Inc 是一家临床阶段的生物制药公司，致力于通过开发差异化药物来重新定义人类疾病的治疗，解决健康问题并显著改善患者的生活。它致力于采用新技术来解决已知病因生物学的靶点，但尚未被药物化，或药物化不足，通常基于现有技术的局限性。其方法旨在以疾病无关的方式发现和开发新一代药物。其产品管线包括 STAT6、TYK2 和 IRAK4。</p>
<h3>理解数字：Kymera Therapeutics 的财务状况</h3>
<p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相对于同行的规模相对较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
<p><strong>负面收入趋势：</strong> 检查 Kymera Therapeutics 在过去 3 个月的财务状况显示出挑战。截至 2025 年 9 月 30 日，该公司经历了约 <strong>-26.12%</strong> 的收入增长下降，反映出顶线收益的减少。与医疗保健行业的其他公司相比，该公司的增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> Kymera Therapeutics 的净利润率低于行业平均水平，表明在实现强劲盈利能力方面面临挑战。其净利润率为 <strong>-2973.05%</strong>，公司可能在有效成本管理方面面临困难。</p>
<p><strong>股本回报率 (ROE)：</strong> Kymera Therapeutics 的 ROE 低于行业平均水平，表明在有效利用股本方面面临挑战。该公司的 ROE 为 <strong>-8.57%，</strong> 可能在为股东创造最佳回报方面遇到困难。</p>
<p><strong>资产回报率 (ROA)：</strong> Kymera Therapeutics 的 ROA 低于行业平均水平，表明在有效利用资产方面面临挑战。该公司的 ROA 为 <strong>-7.36%，</strong> 可能在从其资产中产生最佳回报方面遇到困难。</p>
<p><strong>债务管理：</strong> Kymera Therapeutics 的债务与股本比率为 <strong>0.09，</strong> 低于平均水平，表明其采取了谨慎的财务策略，显示出对债务管理的平衡态度。</p>
<h2>分析师评级的核心：每位投资者应知晓的事项</h2>
<p>Benzinga 跟踪 150 家分析师公司并报告其股票预期。分析师通常通过预测公司未来的盈利能力，通常是未来五年，以及该公司收入来源的风险或可预测性来得出结论。</p>
<p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或在公司有重大更新时进行评级。</p>
<p>除了他们的评估外，一些分析师还通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师也是人，只能根据他们的信念提供预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

<p>Kymera Therapeutics（纳斯达克代码：KYMR）在过去三个月内获得了 21 位分析师的褒贬不一的评价，平均 12 个月目标价为 120.05 美元，比之前的目标上涨了 44.97%。最近的评级显示出向看涨情绪的转变，多位分析师显著提高了他们的目标价。然而，该公司面临财务挑战，包括收入增长下降 26.12% 和净利润率为-2973.05%。尽管面临这些困难，Kymera 仍保持谨慎的债务管理策略，债务与股本比率低至 0.09</p>

<p>During the last three months, 21 analysts shared their evaluations of Kymera Therapeutics (NASDAQ: KYMR), revealing diverse outlooks from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，21 位分析师分享了他们对 Kymera Therapeutics（纳斯达克：KYMR）的评估，展现出从看涨到看跌的多样化前景。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快速概览，突显了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $120.05, with a high estimate of $138.00 and a low estimate of $80.00. Observing a 44.97% increase, the current average has risen from the previous average price target of $82.81.</p>
<div class="lb-trans"><p>分析师对 12 个月价格目标的评估提供了额外的见解，显示出平均目标为 120.05 美元，最高预估为 138.00 美元，最低预估为 80.00 美元。观察到 44.97% 的增长，目前的平均值已从之前的 82.81 美元上升。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770127235_0.png"/></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<div class="lb-trans"><h2>分析师评级探讨：深入概述</h2>
</div><p>A comprehensive examination of how financial experts perceive Kymera Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对金融专家如何看待 Kymera Therapeutics 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及评级和价格目标调整的详细总结。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$117.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$127.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$118.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上调</td>
<td>超配</td>
<td>$133.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>上调</td>
<td>买入</td>
<td>$117.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超配</td>
<td>$103.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>上调</td>
<td>超配</td>
<td>$110.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Mizuho</td>
<td>上调</td>
<td>超配</td>
<td>$120.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>$125.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>上调</td>
<td>买入</td>
<td>$122.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>上调</td>
<td>买入</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>$116.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$116.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>上调</td>
<td>超配</td>
<td>$120.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>$127.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上调</td>
<td>超配</td>
<td>$119.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$125.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>上调</td>
<td>买入</td>
<td>$134.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>上调</td>
<td>超配</td>
<td>$118.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>上调</td>
<td>买入</td>
<td>$112.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>上调</td>
<td>买入</td>
<td>$138.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Kymera Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Kymera Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’，都反映了他们对 Kymera Therapeutics 最近发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师对股票进行定性评估，范围从 ‘超配’ 到 ‘低配’。这些评级传达了分析师对 Kymera Therapeutics 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供 Kymera Therapeutics 未来价值的估计。检查当前和之前的目标提供了分析师预期变化的见解。</li>
</ul>
</div><p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Kymera Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与关键财务指标结合起来，可以提供 Kymera Therapeutics 市场地位的全面概述。保持信息灵通，并在我们的评级表的帮助下做出明智的决策。</p>
</div><p>Stay up to date on Kymera Therapeutics analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Kymera Therapeutics 的分析师评级。</p>
</div><h2>About Kymera Therapeutics</h2>
<div class="lb-trans"><h2>关于 Kymera Therapeutics</h2>
</div><p>Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.</p>
<div class="lb-trans"><p>Kymera Therapeutics Inc 是一家临床阶段的生物制药公司，致力于通过开发差异化药物来重新定义人类疾病的治疗，解决健康问题并显著改善患者的生活。它致力于采用新技术来解决已知病因生物学的靶点，但尚未被药物化，或药物化不足，通常基于现有技术的局限性。其方法旨在以疾病无关的方式发现和开发新一代药物。其产品管线包括 STAT6、TYK2 和 IRAK4。</p>
</div><h3>Understanding the Numbers: Kymera Therapeutics's Finances</h3>
<div class="lb-trans"><h3>理解数字：Kymera Therapeutics 的财务状况</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相对于同行的规模相对较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
</div><p><strong>Negative Revenue Trend:</strong> Examining Kymera Therapeutics's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately <strong>-26.12%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>负面收入趋势：</strong> 检查 Kymera Therapeutics 在过去 3 个月的财务状况显示出挑战。截至 2025 年 9 月 30 日，该公司经历了约 <strong>-26.12%</strong> 的收入增长下降，反映出顶线收益的减少。与医疗保健行业的其他公司相比，该公司的增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Kymera Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-2973.05%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Kymera Therapeutics 的净利润率低于行业平均水平，表明在实现强劲盈利能力方面面临挑战。其净利润率为 <strong>-2973.05%</strong>，公司可能在有效成本管理方面面临困难。</p>
</div><p><strong>Return on Equity (ROE):</strong> Kymera Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-8.57%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回报率 (ROE)：</strong> Kymera Therapeutics 的 ROE 低于行业平均水平，表明在有效利用股本方面面临挑战。该公司的 ROE 为 <strong>-8.57%，</strong> 可能在为股东创造最佳回报方面遇到困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> Kymera Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.36%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率 (ROA)：</strong> Kymera Therapeutics 的 ROA 低于行业平均水平，表明在有效利用资产方面面临挑战。该公司的 ROA 为 <strong>-7.36%，</strong> 可能在从其资产中产生最佳回报方面遇到困难。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Kymera Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Kymera Therapeutics 的债务与股本比率为 <strong>0.09，</strong> 低于平均水平，表明其采取了谨慎的财务策略，显示出对债务管理的平衡态度。</p>
</div><h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<div class="lb-trans"><h2>分析师评级的核心：每位投资者应知晓的事项</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟踪 150 家分析师公司并报告其股票预期。分析师通常通过预测公司未来的盈利能力，通常是未来五年，以及该公司收入来源的风险或可预测性来得出结论。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或在公司有重大更新时进行评级。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他们的评估外，一些分析师还通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师也是人，只能根据他们的信念提供预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

深入分析 Kymera Therapeutics 股票：分析师观点（21 个评级）